Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 5.84% is 112% above its 5-year average of -47.67%, near the high end of its 5-year range (-76.79%–5.84%).
126.62% above its 12-month average of -21.93%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 3.07%.
RETURN ON ASSETS (ROA)
5.84%
RETURN ON ASSETS (ROA) AVG TTM
-21.93%
RETURN ON ASSETS (ROA) AVG 3Y
-47.49%
RETURN ON ASSETS (ROA) AVG 5Y
-47.67%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+126.62%
CURRENT VS 3Y AVG
+112.30%
CURRENT VS 5Y AVG
+112.25%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.70%
median of 727 covered companies
CURRENT VS SECTOR MEDIAN
+119.02%
vs the sector median at left
Arcutis Biotherapeutics, Inc.
Market Cap
$3.07B
Return on Assets (ROA)
5.84%
TTM Avg
-21.93%
3Y Avg
-47.49%
5Y Avg
-47.67%
Market Cap
$3.07B
Return on Assets (ROA)
-11.64%
TTM Avg
-24.55%
3Y Avg
-30.16%
5Y Avg
-27.23%
Market Cap
$3.07B
Return on Assets (ROA)
-57.49%
TTM Avg
-99.67%
3Y Avg
-60.13%
5Y Avg
-103.92%
Market Cap
$3.14B
Return on Assets (ROA)
-44.17%
TTM Avg
-37.77%
3Y Avg
-27.61%
5Y Avg
-21.12%
Market Cap
$2.88B
Return on Assets (ROA)
-52.25%
TTM Avg
-41.76%
3Y Avg
-70.33%
5Y Avg
-55.50%
Market Cap
$2.81B
Return on Assets (ROA)
10.36%
TTM Avg
11.11%
3Y Avg
1.40%
5Y Avg
-7.68%
Market Cap
$2.80B
Return on Assets (ROA)
1.56%
TTM Avg
-4.54%
3Y Avg
-5.50%
5Y Avg
-3.43%
Market Cap
$3.34B
Return on Assets (ROA)
-180.51%
TTM Avg
-129.75%
3Y Avg
-129.75%
5Y Avg
-129.75%
Market Cap
$3.41B
Return on Assets (ROA)
20.83%
TTM Avg
2.76%
3Y Avg
-12.34%
5Y Avg
-9.97%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | $3.07B | 5.84% | -21.93% | -47.49% | -47.67% |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.07B | -11.64% | -24.55% | -30.16% | -27.23% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.07B | -57.49% | -99.67% | -60.13% | -103.92% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.14B | -44.17% | -37.77% | -27.61% | -21.12% |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.88B | -52.25% | -41.76% | -70.33% | -55.50% |
| TransMedics Group, Inc. (TMDX)vs › | $2.81B | 10.36% | 11.11% | 1.40% | -7.68% |
| AtriCure, Inc. (ATRC)vs › | $2.80B | 1.56% | -4.54% | -5.50% | -3.43% |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.34B | -180.51% | -129.75% | -129.75% | -129.75% |
| CareDx, Inc (CDNA)vs › | $3.41B | 20.83% | 2.76% | -12.34% | -9.97% |
| Precigen, Inc. (PGEN)vs › | $2.72B | -92.61% | -123.47% | -74.33% | -62.85% |
ROA
5.8%
ROE
12.9%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -3.73% |
| 2024-12-31 | -40.14% |
| 2023-12-31 | -76.79% |
| 2022-12-31 | -69.32% |
| 2021-12-31 | -50.56% |
| 2020-12-31 | -45.49% |
| 2019-12-31 | -39.24% |
| 2018-12-31 | -37.68% |
| 2017-12-31 | -130.35% |
